Overview

* Bionano Q3 2025 revenue grows 21% yr/yr, beating analyst expectations

* Company's gross margin improves to 46% from (139)% in Q3 2024

* Operating expenses reduced by 66% to $11.9 mln

Outlook

* Bionano expects Q4 2025 revenue between $7.5 mln and $7.9 mln

* Company maintains full-year 2025 revenue guidance of $26 mln to $30 mln

* Bionano anticipates over 25 new OGM system installations in 2025

Result Drivers

* CONSUMABLES AND SOFTWARE - Increased utilization among routine users drove revenue growth, per CEO Erik Holmlin

* EXPANSION IN JAPAN - Growing utilization of optical genome mapping in Japan supports revenue growth

* OGM SYSTEM INSTALLATIONS - Installation of new OGM systems contributed to revenue increase

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $7.40 $6.87

Revenue mln mln (3

Analysts

)

Q3 Gross 46.00%

Margin

Q3 $9.70

Adjusted mln

Operatin

g

Expenses

Q3 $11.90

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Bionano Genomics Inc ( BNGO ) is $9.50, about 83.2% above its November 12 closing price of $1.60

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)